POSTER PRESENTATION
ADC Organoid Screen
Predict the therapeutic effect of your ADCs with patient-derived organoid technology
Directly derived from patient tissue and never passaged in host animals
Test off-tumor toxicities of your ADCs in matched normal organoids
Recapitulates the structure, function, and cellular profiles of patient tumor
Reflects variability observed in patient response, despite similar antigen expression
THE CHALLENGE
Antibody-drug conjugates (ADCs) have achieved significant milestones, with 15 FDA approvals since 2000, due to their targeted mechanism of action. However, the drug development process remains highly complex, largely due to intricate pharmacodynamics and the limitations of current experimental systems. For instance, cell lines often overexpress target antigens, which can result in efficacy assessments that do not accurately reflect clinical conditions. Although patient-derived xenograft (PDX) models offer a more accurate representation of human tumors, they are expensive and may not capture the full spectrum of tumor variations. Furthermore, animal models often fall short in mimicking the complexity of human tumor biology and immune responses, with species differences further complicating the translation of preclinical findings to clinical outcomes.
Our cutting-edge flow cytometry platform provides unparalleled accuracy in assessing both internal and external target antigen (TAA) expression in patient-derived organoids. Our comprehensive analysis empowers you to:
Explore the activity of ADC candidates across one or multiple tumor types. Identify oncological indications most susceptible to treatment in a customized basket screening. Our available readouts are:
Explore the activity and safety profile of ADC candidates in a panel of tumor and normal organoids. Pick from a panel of oncological indications. Our available readouts are:
POSTER PRESENTATION
BLOG
